

**DAVID FELDMAN, M.D.**  
**Professor of Medicine, Emeritus**  
**Division of Endocrinology**  
**Stanford University School of Medicine**  
**Stanford, CA 94305**

**EDUCATION**

1955-1959 B.A.                    New York University, Bronx, NY  
1959-1963 M.D.                    New York University School of Medicine, New York, NY  
1970-1972 M.S.                    Biochemistry, University of California, San Francisco, CA

**ACADEMIC AND PROFESSIONAL POSITIONS**

- 1963-1967                    Intern, Resident, and Chief Resident  
                                  New York University-Bellevue Medical Center, New York, NY
- 1967-1969                    Internist, United States Air Force Hospital, Wright-Patterson Air Force Base, Dayton, OH
- 1969-1970                    Post-Doctoral Fellow, Division of Endocrinology, Harbor General Hospital, (UCLA) Los Angeles, CA,
- 1970-1972                    Post-Doctoral Fellow, Cardiovascular Research Institute and Department of Medicine, University of California, San Francisco,
- 1972-1974                    Assistant Professor, Department of Medicine, Northwestern University Medical School, Research and Education Associate, V.A. Research Hospital, Chicago, IL
- 1974-1979                    Assistant Professor, Department of Medicine, Stanford University School of Medicine, Stanford, CA
- 1979-1984                    Associate Professor, Department of Medicine, Stanford University School of Medicine, Stanford, CA
- 1981-1990                    Chief, Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
- 1984-2007                    Professor, Department of Medicine Stanford University School of Medicine, Stanford CA
- 2007-current                  Professor, Emeritus (active), Department of Medicine Stanford University School of Medicine, Stanford CA
- 2015-present                  Professor, Emeritus, Department of Medicine Stanford University

## **HONORS AND AWARDS**

Phi Beta Kappa, 1959

Herman Wortis Award, New York University School of Medicine, 1963

Diplomate, American Board of Internal Medicine, 1969

Investigator, Howard Hughes Medical Institute, 1976-1981

CapCure Awards for prostate cancer research, 1995, 2001

Outstanding Contributions to Vitamin D Research, Career Award, Vitamin D Workshop 2009

## **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

American Federation for Clinical Research

Western Society for Clinical Research

Endocrine Society

American Physiological Society

American Society for Clinical Investigation

American Society for Bone and Mineral Research

Association of American Physicians

American Association for Cancer Research

## **PROFESSIONAL ACTIVITIES**

1976-1981	Investigator, Howard Hughes Medical Institute
1978-1983	Editorial Board, Endocrinology
1982-1983	Editorial Board, American College of Physicians' Medical Knowledge Self Assessment Program VI (MKSAP VI)
1983-1986	Council, American Society for Bone and Mineral Research
1985-1996	Publications Committee, Journal of Bone and Mineral Research
1985 Summer	Cold Spring Harbor: Molecular Cloning of Eukaryotic Genes
1985-1986	Visiting Professor, Medigen Laboratory (L. Kedes), Palo Alto Veterans Administration Medical Center
1986 Summer	Visiting Professor, University of California at San Francisco, Laboratory of K. Yamamoto
1986-1991	Editorial Board, Journal of Clinical Endocrinology & Metabolism
1992-2000, 2004-08	Editorial Board, Endocrinology
1995, 2001	Investigator, CaP CURE
1996-2011	Director, Training Grant: Diabetes, Endocrinology & Metabolism
2008-current	Associate Editor, Dermato-Endocrinology

## **BIBLIOGRAPHY**

1. J.W. Funder, D. Feldman, and I.S. Edelman. Specific aldosterone binding in rat kidney and parotid. *J. Steroid Biochem.* 3:209-218, 1972.
2. **D. Feldman, J.W. Funder, and I.S. Edelman. Subcellular mechanisms in the action of adrenal steroids. Amer. J. Med. 53:545-560, 1972.**
3. **J.W. Funder, D. Feldman, and I.S. Edelman. The roles of plasma binding and receptor**

**specificity in the mineralocorticoid action of aldosterone. Endocrinology 92:994-1004, 1973.**

4. J.W. Funder, D. Feldman, and I.S. Edelman. Glucocorticoid receptors in the rat kidney: The binding of tritiated-dexamethasone. *Endocrinology* 92:1005-1013, 1973.
5. D. Feldman and J.W. Funder. The binding of 18-hydroxydeoxycorticosterone and 18-hydroxycorticosterone to mineralocorticoid and glucocorticoid receptors in the rat kidney. *Endocrinology* 92:1389-1396, 1973.
6. D. Feldman, J.W. Funder, and I.S. Edelman. Evidence for a new class of corticosterone receptors in rat kidney. *Endocrinology* 92:1429-1441, 1973.
7. J.W. Funder, D. Feldman, E. Highland, and I.S. Edelman. Molecular modifications of anti-aldosterone compounds: Effects on affinity for renal aldosterone receptors. *Biochem. Pharmacol.* 23:1493-1501, 1974.
8. D. Feldman. Mineralocorticoid receptors and 18-hydroxydeoxy-corticosterone binding in the kidney of the spontaneously hypertensive rat. *Endocrinology* 94:1185-1199, 1974.
9. D. Feldman. Adrenal cortex steroids. *McGraw-Hill Yearbook of Science and Technology* 95-97, 1974.
10. **D. Marver, J. Stewart, J.W. Funder, D. Feldman, and I.S. Edelman. Renal aldosterone receptors: Studies with [<sup>3</sup>H]aldosterone and the anti-mineralocorticoid [<sup>3</sup>H]spirolactone (SC 26304). Proc. Nat. Sci., U.S.A. 71:1431-1435, 1974.**
11. D. Feldman. Ontogeny of rat hepatic glucocorticoid receptors. *Endocrinology* 95:1219-1227, 1974.
12. D. Feldman, R. Dziak, R. Koehler, and P. Stern. Cytoplasmic glucocorticoid binding proteins in bone cells. *Endocrinology* 96:29-36, 1975.
13. D. Feldman. The role of hormone receptors in the action of adrenal steroids. *Ann. Rev. Med.* 26:83-90, 1975.
14. M.E. Wolff, D. Feldman, P. Catsoulacos, J.W. Funder, C. Hancock, Y. Amano, and I.S. Edelman. Steroidal 21-diazo ketones: Photo-generated corticosteroid receptor labels. *Biochemistry* 14:1750-1759, 1975.
15. J.M. Strum, D. Feldman, B. Taggart, D. Marver, and I.S. Edelman. Autoradiographic localization of corticosterone receptors (Type III) to the collecting tubule of the rat kidney. *Endocrinology* 97:505-516, 1975.
16. **D. Feldman and C. Couropmitree. Intrinsic mineralocorticoid agonist activity of some non-steroidal anti-inflammatory drugs: A postulated mechanism for sodium retention. J. Clin. Invest. 57:107, 1976.**
17. C. Sakauye and D. Feldman. Agonist and anti-mineralocorticoid activities of spirolactones. *Am.*

J. Physiol. 231:93-97, 1976.

18. J.W. Funder, J.A. Robinson, D. Feldman, K.N. Wynne, and W.R. Adam.  $16\beta$  hydroxydehydroepiandrosterone; The dichotomy between renal receptor binding and urinary electrolyte activity. Endocrinology 99:619-628, 1976.
19. D. Feldman and D. Loose. Glucocorticoid receptors in adipose tissue. Endocrinology 100:398-405, 1977.
20. T.L. Chen, L. Aronow, and D. Feldman. Glucocorticoid receptors and inhibition of bone cell growth in primary culture. Endocrinology 100:619-628, 1977.
21. D. Feldman. Glucocorticoid receptors and the regulation of phosphoenolpyruvate-carboxykinase activity in rat kidney and adipose tissue. Am. J. Physiol. 233:E147-E151, 1977.
22. T.L. Chen and D. Feldman. Distinction between alpha-fetoprotein and intracellular estrogen receptors: Evidence against the presence of estradiol receptors in rat bone. Endocrinology 102:236-244, 1978.
23. T.L. Chen and D. Feldman. Glucocorticoid potentiation of the adenosine 3',5'-monophosphate response to parathyroid hormone in cultured rat bone cells. Endocrinology 102:589-596, 1978.
24. D. Feldman. Binding of some non-steroidal anti-inflammatory drugs to glucocorticoid receptors *in vitro*. Biochem. Pharmacol. 27:1187-1191, 1978.
25. J. Choe, P. Stern, and D. Feldman. Receptor mediated glucocorticoid inhibition of protein synthesis in isolated bone cells. J. Steroid Biochem. 9:265-271, 1978.
26. D. Feldman, J. Funder, and D. Loose. Is the glucocorticoid receptor identical in various target organs? J. Steroid Biochem. 9:141-145, 1978.
27. D. Feldman, D.S. Loose, and S.Y. Tan. Non-steroidal anti-inflammatory drugs cause sodium and water retention in the rat. Am. J. Physiol. 234:F490-496, 1978.
28. D. Feldman and M. Hirst. Glucocorticoids and the regulation of phosphoenol-pyruvate-carboxykinase activity in rat brown adipose tissue. Am. J. Physiol. 235:197-202, 1978.
29. J.W. Funder, J. Mercer, B. Ingram, D. Feldman, K. Wynne, and W.R. Adam. 19-nor-deoxycorticosterone (19-nor DOC): Mineralocorticoid receptor affinity higher than aldosterone, electrolyte activity lower. Endocrinology 103:1514-1517, 1978.
30. **D. Feldman. Mineralocorticoid antagonists: The relationship of drug structure to receptor binding and biological action. In: Aldosterone Antagonists in Clinical Medicine. Excerpta Medica, Amsterdam, 1978.**
31. D. Feldman. Evidence that brown adipose tissue is a glucocorticoid target organ. Endocrinology 103:2091-2097, 1979.

32. J.N. Weiser, Y.S. Do, and D. Feldman. Synthesis and secretion of corticosteroid-binding globulin by rat liver: A source of heterogeneity of hepatic corticosteroid-binders. *J. Clin. Invest.* 63:461-467, 1979.
33. T.L. Chen and D. Feldman. Glucocorticoid receptors and actions in subpopulations of cultured bone cells: Mechanism of dexamethasone potentiation of parathyroid hormone stimulated cyclic AMP. *J. Clin. Invest.* 63:750-758, 1979.
34. T.L. Chen, M.A. Hirst, and D. Feldman. A receptor-like binding macro-molecule for 1, $\alpha$ -25-dihydroxycholecalciferol in cultured mouse bone cells. *J. Biol. Chem.* 254:7491-7494, 1979.
35. D. Feldman, T.A. McCain, M.A. Hirst, T.L. Chen, and K.W. Colston. Characterization of a cytoplasmic receptor-like binder for 1 $\alpha$ ,25-dihydroxycholecalciferol in rat intestinal mucosa. *J. Biol. Chem.* 254:l0378-l0384, 1979.
36. Y.S. Do, D.S. Loose, and D. Feldman. Heterogeneity of glucocorticoid binders. A unique and a classical dexamethasone binding site in bovine tissues. *Endocrinology* l05:1055-1063, 1979.
37. K.W. Colston and D. Feldman. Demonstration of a 1 $\alpha$ ,25-dihydroxycholecalciferol cytoplasmic receptor-like binder in mouse kidney cytosol. *J. Clin. Endocrinol. Metab.* 49:798-800, 1979.
38. D. Feldman, C.E. Mondon, J. A. Horner, and J.N. Weiser. Glucocorticoid and estrogen regulation of corticosteroid binding globulin production by rat liver. *Am. J. Physiol.* 237:493-499, 1979.
39. D.S. Loose, Y.S. Do, T.L. Chen, and D. Feldman. Demonstration of glucocorticoid receptors in the adrenal cortex: Evidence for a direct dexamethasone suppressive effect on the rat adrenal gland. *Endocrinology* l07:l37-l46, 1980.
40. K. Colston and D. Feldman. Nuclear translocation of the 1,25-dihydroxycholecalciferol receptor in mouse kidney. *J. Biol. Chem.* 255:7510-7513, 1980.
41. Y.S. Do and D. Feldman. Heterogeneity of glucocorticoid binders: A high affinity triamcinolone acetonide binder in bovine serum. *Endocrinology* l07:l370-l375, 1980.
42. D. Feldman, T. Chen, M. Hirst, K. Colston, M. Karasek, and C. Cone. Demonstration of 1,25-dihydroxyvitamin D<sub>3</sub> receptors in human skin biopsies. *J. Clin. Endocrinol. Metab.* 51:1463-1465, 1980.
43. K. Colston, M. Hirst, and D. Feldman. Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. *Endocrinology* l07:l916-l922, 1980.
44. K. Colston, M. Joseph Colston and D. Feldman. 1,25-Dihydroxyvitamin D<sub>3</sub> and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. *Endocrinology* 108:1083-1086, 1981.

45. M.A. Hirst and D. Feldman. 1,25-Dihydroxyvitamin D<sub>3</sub> receptors in mouse colon. *J. Steroid Biochem.* 14:315-319, 1981.
46. T.L. Chen and D. Feldman. Regulation of 1,25-Dihydroxyvitamin D<sub>3</sub> receptors in cultured mouse bone cells. Correlation of receptor concentration with the rate of cell division. *J. Biol. Chem.* 256:5561-5566, 1981.
47. D.S. Loose, D. Schurman and D. Feldman. A corticosteroid binding protein and endogenous ligand in *C. albicans* indicating a possible steroid-receptor system. *Nature* 293:477-479, 1981.
48. K. Colston and D. Feldman. 1,25-Dihydroxyvitamin D<sub>3</sub> receptors and functions in cultured pig kidney cells (LLC PK<sub>1</sub>). *J. Biol. Chem.* 257:2504-2508, 1982.
49. K. Colston, M.J. Colston, A.H. Fieldsteel and D. Feldman. 1,25-Dihydroxyvitamin D<sub>3</sub> receptors in human epithelial cancer cell lines. *Cancer Res.* 42:856-859, 1982.
50. D.S. Loose and D. Feldman. Characterization of a unique corticosterone-binding protein in *Candida albicans*. *J. Biol. Chem.* 257:4925-4930, 1982.
51. M. Hirst and D. Feldman. Glucocorticoids down-regulate the number of 1,25-dihydroxyvitamin D<sub>3</sub> receptors in mouse intestine. *Biochem. Biophys. Res. Comm.* 105:1590-1596, 1982.
52. Pont, P.L. Williams, D.S. Loose, D. Feldman, R.E. Reitz, C. Bochra and D.A. Stevens. Ketoconazole blocks adrenal steroid synthesis. *Ann. Int. Med.* 97:370-372, 1982.
53. M. Hirst and D. Feldman. Glucocorticoid regulation of 1,25(OH)<sub>2</sub>vitamin D<sub>3</sub> receptors: Divergent effects on mouse and rat intestine. *Endocrinology* 93:1400-1402, 1982.
54. D. Feldman, Y. Do, A. Bursshell, P. Stathis and D. Loose. An estrogen binding protein and endogenous ligand in the yeast *Saccharomyces cerevisiae*: A possible steroid-receptor system. *Science* 218:297-298, 1982.
55. D. Feldman, T. Chen, C. Cone, M. Hirst, S. Shani, A. Benderli and Z. Hochberg. Vitamin D resistant rickets with alopecia: Cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)<sub>2</sub>D<sub>3</sub>. *J. Clin. Endocrinol. Metab.* 55:1020-1022, 1982.
56. T.L. Chen, C.M. Cone, E. Morey-Holton, and D. Feldman. Glucocorticoid regulation of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> receptors in cultured mouse bone cells. *J. Biol. Chem.* 257:13564-13569, 1982.
57. T.L. Chen, C.M. Cone, E. Morey-Holton and D. Feldman. 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. *J. Biol. Chem.* 258:4350-4355, 1983.
58. T.L. Chen, C.M. Cone and D. Feldman. Glucocorticoid modulation of cell proliferation in cultured osteoblast-like bone cells: Differences between rat and mouse. *Endocrinology* 112:1739-1745, 1983.

59. D.S. Loose, P.B. Kan, M.A. Hirst, R.A. Marcus and D. Feldman. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. *J. Clin. Invest.* 71:1495-1499, 1983.
60. D.S. Loose, E.P. Stover and D. Feldman. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. *J. Clin. Invest.* 72:404-408, 1983.
61. D.S. Loose, D.A. Stevens, D.J. Schurman and D. Feldman. Distribution of a corticosteroid-binding protein in *Candida* and other fungal genera. *J. Gen. Microbiol.* 129:2379-2385, 1983.
62. T.L. Chen, C.M. Cone and D. Feldman. Effects of 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and glucocorticoids on the growth of rat and mouse osteoblast-like bone cells. *Calcif. Tissue Intl.* 35:806-811, 1983.
63. M. Hirst and D. Feldman. Regulation of 1,25(OH)<sub>2</sub>Vitamin D<sub>3</sub> receptor content in cultured LLC-PK<sub>1</sub> kidney cells limits hormonal responsiveness. *Biochem. Biophys. Res. Comm.* 116:121-127, 1983.
64. D.S. Loose, E.P. Stover, A. Restrepo, D.A. Stevens and D. Feldman. Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in *Paracoccidioides brasiliensis*. *Proc. Natl. Acad. Sci.* 80:7659-7663, 1983.
65. E.P. Stover, D.S. Loose, D.A. Stevens and D. Feldman. Ketoconazole binds to the intracellular corticosteroid-binding protein in *Candida albicans*. *Biochem. Biophys. Res. Comm.* 117:43-50, 1983.
66. Bursshell, P.A. Stathis, Y. Do, S.C. Miller and D. Feldman. Characterization of an estrogen-binding protein in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* 259:3450-3456, 1984.
67. D. Feldman, P.A. Stathis, M.A. Hirst, E.P. Stover, Y.S. Do and W. Kurz. *Saccharomyces cerevisiae* produces a yeast substance that exhibits estrogenic activity in mammalian systems. *Science* 224:1109-1111, 1984.
68. R.L. Wagner, P.F. White, P.B. Kan, M.H. Rosenthal and D. Feldman. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. *N. Engl. J. Med.* 310:1415-1421, 1984.
69. T.L. Chen, M.A. Hirst, C.M. Cone, Z. Hochberg, H.-U. Tietze and D. Feldman. 1,25-Dihydroxyvitamin D resistance, rickets and alopecia: Analysis of receptors and bioresponse in cultured fibroblasts from patients and parents. *J. Clin. Endocrinol. Metab.* 59:383-388, 1984.
70. Bennett, T. Chen, D. Feldman, R.L. Hintz and R.G. Rosenfeld. Characterization of somatomedin C/insulin-like growth factor-I receptors in cultured rat bone cells: regulation of receptor concentration by glucocorticoids. *Endocrinology* 115:1577-1583, 1984.
71. D. Feldman, L.G. Tokes, P.A. Stathis, S.C. Miller, W. Kurz and D. Harvey. Identification of 17  $\beta$ -estradiol as the estrogenic substance in *Saccharomyces cerevisiae*. *Proc. Natl. Acad. Sci.*

81:4722-4726, 1984.

72. Z. Hochberg, A. Benderli, J. Levy, P. Vardi, Y. Weisman, T. Chen and D. Feldman. 1,25-Dihydroxyvitamin D resistance, rickets and alopecia. Am. J. Med. 77:805-811, 1984.
73. T.L. Chen and D. Feldman. Modulation of PTH-stimulated cyclic AMP in cultured rodent bone cells: The effects of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and its interaction with glucocorticoids. Calcif. Tissue Int. 36:580-585, 1984.
74. Restreppo, M.E. Salazar, L.E. Cano, E.P. Stover, D. Feldman and D.A. Stevens. Estrogens inhibit mycelium-to-yeast transformation in the fungus *Paracoccidioides brasiliensis*: Implications for resistance of females to Paracoccidioidomycosis. Infect. Immun. 46:346-353, 1984.
75. M. A. Hirst, H. I. Hochman, and D. Feldman. Vitamin D resistance and alopecia: a kindred with normal 1,25 dihydroxyvitamin D binding, but decreased receptor affinity for DNA. J. Clin. Endocrinol. Metab. 60:490-495, 1985.
76. T.L. Chen and D. Feldman. Retinoic acid modulation of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> receptors and bioresponse in bone cells: species differences between rat and mouse. Biochem. Biophys. Res. Commun. 132:74-80, 1985.
77. E.M. Costa, M.A. Hirst, and D. Feldman. Regulation of 1,25-dihydroxyvitamin D<sub>3</sub> receptors by vitamin D analogs in cultured mammalian cells. Endocrinology 117:2203-2210, 1985.
78. **P.B. Kan, M.A. Hirst and D. Feldman. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J. Steroid Biochem. 23:1023-1029, 1985.**
79. T.L. Chen, J.M. Li, T. VanYe, C.M. Cone and D. Feldman. Hormonal responses to 1,25-dihydroxyvitamin D<sub>3</sub> in cultured mouse osteoblast-like cells -modulation by changes in receptor level. J. Cell Physiol. 126:21-28, 1986.
80. T.L. Chen, P.V. Hauschka, S. Cabrales and D. Feldman. The effects of 1,25(OH)<sub>2</sub>D<sub>3</sub> and dexamethasone on rat osteoblast-like (OB) primary cell cultures: receptor occupancy and functional expression patterns for three different bioresponses. Endocrinology 118:250-259, 1986.
81. E.P. Stover, G. Schar, K.V. Clemons, D.A. Stevens and D. Feldman. Estradiol-binding proteins from mycelial and yeast-form cultures of *Paracoccidioides brasiliensis*. Infect. Immun. 51:199-203, 1986.
82. T.L. Chen, P.V. Hauschka and D. Feldman. Dexamethasone increases 1,25-dihydroxyvitamin D<sub>3</sub> receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 118: 1119-1126, 1986.
83. G. Schar, E.P. Stover, K.V. Clemons, D. Feldman and D. Stevens. Progesterone binding and inhibition of growth in *Trichophyton mentagrophytes*. Infect. Immun. 52:763-767, 1986.

84. E.M. Costa and D. Feldman. Homologous up-regulation of the 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> receptor in rats. *Biochem. Biophys. Res. Commun.* 137:742-747, 1986.
85. S.C. Miller, C.D.K. Bottema, P.A. Stathis, LG. Tokes and D. Feldman. Unexpected presence of estrogens in culture medium supplements: Subsequent metabolism by the yeast *Saccharomyces cerevisiae*. *Endocrinology* 119:1362-1368, 1986.
86. E.M. Costa, H.M. Blau and D. Feldman. 1,25-DihydroxyvitaminD<sub>3</sub> receptors and hormonal responses in cloned human skeletal muscle cells. *Endocrinology* 119:2214-2220, 1986.
87. M. Hirst and D. Feldman. Cleavage of the rat intestinal 1,25-Dihydroxyvitamin D<sub>3</sub> receptor by an endogenous protease to a form with defective DNA binding. *Arch. Biochem. Biophys.* 25:153-161, 1986.
88. **D. Feldman. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis.** *Endocrin. Rev.* 7: 409-420, 1986.
89. D. Feldman. Steroid-binding proteins in yeast. In: Binding Proteins of Steroid Hormones. Colloque INSERM vol 149, M.G. Forest and M. Pugeat, eds. John Libbey Eurotext Ltd., London 149:499-507, 1986.
90. **D. Feldman. Imidazole antifungal drugs: New actions as steroidogenesis inhibitors and glucocorticoid antagonists.** In: Recent Advances in Adrenal Regulation and Function, R. D'Agata and G.P. Chrousos, editors. Serono Symposia Publications, Raven Press, N.Y. 40:243-252, 1987.
91. E.M. Costa and D. Feldman. Measurement of 1,25-dihydroxyvitamin D<sub>3</sub> receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. *Endocrinology* 120:1173-1178, 1987.
92. E.M. Costa and D. Feldman. Modulation of 1,25-dihydroxyvitamin D<sub>3</sub> receptor binding and action by sodium butyrate in cultured pig kidney cells (LLC-PK<sub>1</sub>). *J. Bone Mineral Res.* 2:151-159, 1987.
93. E.P. Stover, A.V. Krishnan, D. Feldman. Estrogen down-regulation of androgen receptors in cultured human mammary cancer cells (MCF-7). *Endocrinology* 120:2597-2603, 1987.
94. M. Hirst and D. Feldman. Salt-induced activation of 1,25-dihydroxyvitamin D<sub>3</sub> receptors to a DNA binding form. *J. Biol. Chem.* 262:7072-7075, 1987.
95. T.K. Gray, N.W. Kleckner, P.J. Malloy, D. Feldman, G. Sivam, R.C. Dodd and M.S. Cohen. Biological activity of 19-nor, 10-keto, 25-hydroxyvitamin D<sub>3</sub>. *J. Bone Mineral Res.* 2:413-419, 1987.
96. D. Feldman and A.V. Krishnan. Glucocorticoid effects on calcium metabolism and bone in the development of osteopenia In, Osteoporosis 1987. C. Christiansen, J.S. Johansen and B.J. Riis editors, pp. 1006-1013, Osteopress, Copenhagen, 1987.

97. D. Feldman. Evidence for the presence of steroid hormone receptors in fungi In, Steroid Hormone Action. G. Ringold, editor, pp. 169-176, Alan R. Liss, Inc. 1988.
98. **D. Feldman. Mechanism of action of cortisol. In: Endocrinology (Second Edition) L. J. DeGroot, Editor. W.B. Saunders Co. Philadelphia** 1988, pp 1557-1571.
99. K.V. Clemons, G. Schar, E.P. Stover, D. Feldman and D.A. Stevens. Dermatophyte-hormone relationships: Characterization of progesterone-binding specificity and growth inhibition in the genera *Trichophyton* and *Microsporum*. *J. Clin. Microb.* 28:2110-2115, 1988.
100. M.R. Hughes, P.J. Malloy, D.G. Kieback, R.A. Kesterson, J.W. Pike, D. Feldman, and B.W. O'Malley. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. *Science* 242:1702-1705, 1988.
101. P.J. Malloy, Z. Hochberg, J.W. Pike, and D. Feldman. Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. *J. Clin. Endocrinol. Metab.* 68:263-269, 1989.
102. R. Skowronski and D. Feldman. Characterization of an estrogen-binding protein in the yeast *Candida albicans*. *Endocrinology* 124:1965-1972, 1989.
103. R. Wade, D. Feldman, P. Gunning, L. Kedes. Sequence and expression of human myosin alkali light chain isoforms. *Molec. Cell. Biochem.* 87:119-136, 1989.
104. K.V. Clemons, D. Feldman and D.A. Stevens. Influence of oestradiol on protein expression and methionine utilization during morphogenesis of *Paracoccidioides brasiliensis*. *J. Gen. Microbiol.* 135:1607-1617, 1989.
105. K.V. Clemons, E.P. Stover, G. Schar, P.A. Stathis, K. Chan, L. Tokes, D.A. Stevens, and D. Feldman. Steroid metabolism as a mechanism of escape from progesterone-mediated growth inhibition by *Trichophyton mentagrophytes*. *J. Biol. Chem.* 264:11186-11192, 1989.
106. D.E. Bruns, A.V. Krishnan, D. Feldman, R.W. Gray, S. Christakos, G.N. Hirsch and M.E. Bruns. Epidermal growth factor increases intestinal calbindin-D<sub>9k</sub> and 1,25-dihydroxyvitamin D receptors in neonatal rats. *Endocrinology* 125:478-485, 1989.
107. T. Sone, R.A. Scott, M.R. Hughes, P.J. Malloy, D. Feldman, B.W. O'Malley, and J.W. Pike. Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D<sub>3</sub> in humans are transcriptionally inactive in vitro. *J. Biol. Chem.* 264:20230-20234, 1989.
108. H.H. Ritchie, M.R. Hughes, E.T. Thompson, P.J. Malloy, Z. Hochberg, D. Feldman, J.W. Pike, and B.W. O'Malley. An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D<sub>3</sub> resistant rickets in three families. *Proc. Natl. Acad. Sci. USA* 86:9783-9787, 1989.
109. M. Hughes, P. Malloy, D. Kieback, D. McDonnell, D. Feldman, J.W. Pike, and B. O'Malley.

- Human vitamin D receptor mutations: Identification of molecular defects in hypocalcemic vitamin D resistant rickets. *Adv. Exp. Med. Biol.* 255:491-503, 1989.
110. D. Feldman and P.J. Malloy. Hereditary 1,25 dihydroxyvitamin D resistant rickets: Molecular basis and implications for the role of 1,25(OH)<sub>2</sub>D<sub>3</sub> in normal physiology. *Molec. Cell Endocrinol.* 72:C57-C62, 1990.
111. P.J. Malloy, Z. Hochberg, D. Tiosano, J.W. Pike, M.R. Hughes, and D. Feldman. The molecular basis of hereditary 1,25-dihydroxyvitamin D<sub>3</sub> resistant rickets in seven related families. *J. Clin. Invest.* 86:2071-2079, 1990.
112. Krishnan and D. Feldman. Activation of protein kinase C inhibits vitamin D receptor gene expression. *Mol. Endocrinol.* 5:605-612, 1991.
113. Krishnan and D. Feldman. Stimulation of 1,25-dihydroxyvitamin D<sub>3</sub> receptor gene expression in cultured cells by serum and growth factors. *J. Bone Mineral Res.* 6:1099-1107, 1991.
114. M.R. Hughes, P.J. Malloy, B.W. O'Malley, J.W. Pike, and D. Feldman. Genetic defects of the 1,25-dihydroxyvitamin D<sub>3</sub> receptor. *J. Recept. Res.* 11:699-716, 1991.
115. **M. Maze, R. Virtanen, D. Daunt, S. Banks, E. P. Stover, and D. Feldman. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: *in vivo* and *in vitro* studies. *Anesth. Analges.* 73:204-208, 1991.**
116. P. J. Malloy, M. R. Hughes, J. W. Pike, and D. Feldman. Vitamin D receptor mutations and hereditary 1,25-dihydroxyvitamin D resistant rickets. In: Vitamin D - Gene Regulation, Structure-Function Analysis and Clinical Application. Proceedings of the Eighth Workshop on Vitamin D, Paris, France (July 5-10, 1991). A. W. Norman, R. Bouillon, M. Thomasset, editors. Walter de Gruyter, NY, 1991, pp. 116-124.
117. K. Denich, P. Malloy and D. Feldman. Cloning and characterization of the gene encoding the ADP-ribosylation factor in *Candida albicans*. *Gene* 110:123-128, 1992.
118. Krishnan and D. Feldman. Cyclic adenosine 3', 5'-monophosphate up-regulates 1,25-dihydroxyvitamin D<sub>3</sub> receptor gene expression and enhances hormone action. *Mol. Endocrinol.* 6:198-206, 1992.
119. J.C. Faig, J. Kalinyak, R. Marcus, and D. Feldman. Chronic atypical seizure disorder and cataracts due to delayed diagnosis of pseudohypoparathyroidism. *West. J. Med.* 157:64-65, 1992.
120. P. Malloy, X. Zhao, N. Madani, and D. Feldman. Cloning and expression of the gene from *Candida albicans* that encodes a high-affinity corticosteroid-binding protein. *Proc. Natl. Acad. Sci. USA* 90:1902-1906, 1993.
121. X. Zhao and D. Feldman. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. *Endocrinology* 132:1808-1814, 1993.

122. R. Skowronski, D. Peehl, and D. Feldman. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D<sub>3</sub> receptors and actions in prostate cancer cell lines. *Endocrinology* 132:1952-1960, 1993.
123. Krishnan, P. Stathis, S.F. Permuth, L. Tokes, and D. Feldman. Bisphenol A: An estrogenic substance is released from polycarbonate flasks during autoclaving. *Endocrinology* 132:2279-2286, 1993.
124. N. Madani, P.J. Malloy, P. Rodriguez-Pombo, A.V. Krishnan, and D. Feldman. *Candida albicans* estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. *Proc. Natl. Acad. Sci. USA* 91:922-926, 1994.
125. D. Peehl, R. Skowronski, G. Leung, S. Wong, T. Stamey, and D. Feldman. Antiproliferative effects of 1,25-dihydroxyvitamin D<sub>3</sub> on primary cultures of human prostatic cells. *Cancer Res.* 54:805-810, 1994.
126. P. Malloy, Y. Weisman, and D. Feldman. Hereditary 1 $\alpha$ ,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. *J. Clin. Endocrinol. Metab.* 78:313-316, 1994.
127. R.J. Skowronski and D. Feldman. Inhibition of aldosterone synthesis in rat adrenal cells by nicotine and related constituents of tobacco smoke. *Endocrinology* 134:2171-2176, 1994.
128. S.A. Lieberman, T.R. Eccleshall, and D. Feldman. ACTH-independent massive bilateral adrenal disease (AIMBAD): A subtype of Cushing's syndrome with major diagnostic and therapeutic implications. *European J. Endocrinol.* 131: 67-73, 1994.
129. D.M. Peehl, R.J. Skowronski, and D. Feldman. Vitamin D and prostate cancer. In: Fundamental Approaches to the Diagnosis and Treatment for Prostate Cancer and BPH. Proceedings of the Fifth Tokyo Symposium on Prostate Cancer, December 16-17, 1993, Keidanren-Kaikan, Tokyo, Japan. K. Imai, J. Shimazaki, J.P. Karr, editors. Adenine Press, New York, 1994, pp. 57-61.
130. P.J. Malloy and D. Feldman. Cloning and expression of the corticosteroid-binding protein gene from *Candida albicans*. In: Molecular Biology of Pathogenic Fungi A Laboratory Manual. B. Maresca and G. Kobayashi, editors. Telos Press, New York, 1994, pp.149-155.
131. D.M. Peehl, R.J. Skowronski, and D. Feldman. Role of vitamin D-receptors in prostate cancer. In: Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. M. Motta and M. Serio, editors. Elsevier Science, Amsterdam, 1994, pp. 23-31.
132. R.J. Skowronski, D.M. Peehl, S. Cramer, and D. Feldman. Actions of 1,25-dihydroxyvitamin D and synthetic analogs on cultured human prostate carcinoma cells. In: Vitamin D:A Pluripotent Steroid Hormone - Structural Studies, Molecular Endocrinology, and Clinical Applications. Proceedings of the Ninth Workshop on Vitamin D, Orlando FL. A.W. Norman, R. Bouillon and M. Thomasset, editors. Walter de Gruyter, New York, 1994.
133. D. Feldman, R.J. Skowronski, and D.M. Peehl. Prostate cancer and vitamin D. In: Advances in Experimental Medicine. AICR, editor. Plenum Press, New York, pp. 53-63, 1995.

134. R.J. Skowronski, D.M. Peehl, and D. Feldman. Actions of vitamin D<sub>3</sub> analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D<sub>3</sub>. *Endocrinology* 136:20-26, 1995.
135. A.V. Krishnan, S.D. Cramer, F.R. Bringhurst, and D. Feldman. Regulation of 1,25-dihydroxyvitamin D<sub>3</sub> receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. *Endocrinology* 136:705-712, 1995.
136. D. Feldman and A. Krishnan. Estrogens in unexpected places: possible implications for researchers and consumers. In: Environmental Health Perspectives Supplements: Estrogens in the Environment; Vol 103 (7): 129-133, 10/1995. NIH, National Institute of Environmental Health Sciences. G.E.R. Hook and G.W. Lucier, editors.
137. X. Zhao, P.J. Malloy, C.M. Ardies, and D. Feldman. Purification and characterization of the estrogen-binding protein in *Candida albicans*: antibody development and cellular localization by electron immunocytochemistry. *Microbiology* 141:2685-2692, 1995.
138. Restrepo, M.E. Salazar, K.V. Clemons, D. Feldman, and D.A. Stevens. Hormonal influences in the host interplay with *Paracoccidioides brasiliensis*. 5th Symposium on Topics in Mycology: Host-Fungus Interplay. Stanford, CA, June 27-30, 1995.
139. D.M. Peehl, S.T. Wong, S.D. Cramer, C. Gross, and D. Feldman. Suramin, hydrocortisone, and retinoic acid modify inhibitory effects of 1,25-dihydroxyvitamin D<sub>3</sub> on prostatic epithelial cells. *Urol. Oncol.* 1:188-194, 1995.
140. Gross, R.J. Skowronski, S.R. Plymate, J.S. Rhim, D.M. Peehl and D. Feldman. Simian virus 40-, but not human papillomavirus-transformation of prostatic epithelial cells, results in loss of growth-inhibition by 1,25-dihydroxyvitamin D<sub>3</sub>. *Int. J. Oncol.* 8:41-47, 1996.
141. L. Kohlmeier and D. Feldman. Adrenal cortex glucocorticoids. In: Current Practice of Medicine, Series Editor R.C. Bone. Vol. 1, Endocrinology and Metabolic Disease. S.G. Korenman, editor. Churchill Livingstone, Inc., New York, 1996, pp. IV:5.1-5.14.
142. R. Marcus, D. Feldman and J. Kelsey, editors. Osteoporosis. Academic Press, Inc., San Diego, 1996, pp 1-1373.
143. Feldman, P.J. Malloy and C. Gross. Vitamin D: Metabolism and Action. In: Osteoporosis. R. Marcus, D. Feldman, and J. Kelsey, editors. Academic Press, Inc., San Diego, 1996, pp. 205-235, 1996.
144. N. U.-T. Lin, P.J. Malloy, N. Sakati, A. Al-Ashwal, and D. Feldman. A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. *J. Clin. Endocrinol. Metab.*, 81:2564-2569, 1996.
145. S.D. Cramer, D.M. Peehl, M.G. Edgar, S.T. Wong, L.J. Deftos, and D. Feldman. Parathyroid hormone-related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. *Prostate* 29:20-29, 1996.

146. L. Van Maldergem, A. Bachy, D. Feldman, R. Bouillon, J. Maassen, M. Dreyer, et al. Syndrome of lipoatrophic diabetes, vitamin D resistant rickets, and persistent mullerian ducts in a Turkish boy born to consanguineous parents. *Am. J. Med. Gen.* 64:506-513, 1996.
147. Gross, T.R Eccleshall, and D. Feldman. Vitamin D receptor gene alleles and osteoporosis. In: Principles of Bone Biology. J.P. Bilezikian, L. G. Raisz, G.A. Rodan, editors. Academic Press, Inc., San Diego, 1996, pp. 917-933.
148. C. Gross, T.R. Eccleshall, P.J. Malloy, M.L. Villa, R. Marcus, and D. Feldman. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. *J. Bone Mineral Res.* 12:1850-1855, 1996.
149. I.M. Musiol and D. Feldman. 1,25-dihydroxyvitamin D<sub>3</sub> induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D<sub>3</sub> analogs. *Endocrinology* 138:12-18, 1997.
150. P.J. Malloy, T.R. Eccleshall, C. Gross, L.Van Maldergen, R. Bouillon, and D. Feldman. Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. *J. Clin. Invest.* 99:297-304, 1997.
151. D. Feldman. Editorial: Androgen and vitamin D receptor gene polymorphisms: The long and short of prostate cancer risk. *J. Natl Cancer Inst.* 89:109-111, 1997.
152. L. McClure, T.R. Eccleshall, C. Gross, M.L. Villa, N. Lin, V. Ramaswamy, L. Kohlmeier, J.L. Kelsey, R. Marcus and D. Feldman. Vitamin D receptor polymorphisms, bone mineral density, and bone metabolism in postmenopausal Mexican-American women. *J. Bone Mineral Res.* 12:234-240, 1997.
153. X-Y Zhao, T.R. Eccleshall, A.V. Krishnan, and D. Feldman. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system. *Mol. Endocrinol.* 11:366-378, 1997.
154. D. Feldman. Editorial: Estrogens from plastic: Are we being exposed? *Endocrinology* 138:1777-1779, 1997.
155. S. S. Harris, T.R. Eccleshall, C. Gross, B. Dawson-Hughes, and D. Feldman. The vitamin D receptor start codon polymorphism (*Fok I*) and bone mineral density in premenopausal American black and white women. *J. Bone Mineral Res.* 12:1043-1048, 1997.
156. X.-Y. Zhao, L.L. Ly, D.M. Peehl, and D. Feldman. 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> actions in LNCaP human prostate cancer cells are androgen-dependent. *Endocrinology* 138:3290-3298, 1997.
157. D. Feldman, F. Glorieux, and J.W. Pike, editors. Vitamin D. Academic Press, Inc., San Diego, 1997. pp 1-1285.

158. Krishnan and D. Feldman. Regulation of vitamin D receptor abundance. In: D. Feldman, F. Glorieux, and J.W. Pike, editors. *In: Vitamin D*. Academic Press, Inc., San Diego, 1997, pp 179-200.
159. P. J. Malloy, J.W. Pike and D. Feldman. Hereditary vitamin D resistant rickets. In: D. Feldman, F. Glorieux, and J.W. Pike, editors. *Vitamin D*. Academic Press, Inc., San Diego, 1997, pp 765-788.
160. C. Gross, D. M. Peehl and D. Feldman. Vitamin D and prostate cancer. In: D. Feldman, F. Glorieux, and J.W. Pike, editors. *Vitamin D*. Academic Press, Inc., San Diego, 1997, pp 1125-1140.
161. J. Buckman, S. M. Miller, P. Malloy and D. Feldman. Properties of an estrogen binding protein from *Candida albicans* - A homolog of OYE. In: *Flavins and Flavoproteins*. K.J. Stevenson, V. Massey and C. H. Williams, Jr. editors. University of Calgary Press, Calgary Canada, 1997, pp 81-84.
162. T. R. Eccleshall, P. Garnero, C. Gross, P. D. Delmas and D. Feldman. Lack of correlation between start codon polymorphism of the vitamin D receptor and bone mineral density in premenopausal French women: the OFELY study. *J. Bone Mineral Res.* 13:31-35, 1998.
163. W. Zhu, P. J. Malloy, E. Delvin, G. Chabot, and D. Feldman. Hereditary 1,25-dihydroxy-vitamin D resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor. *J. Bone Mineral Res.* 13:259-264, 1998.
164. Gross, I. M. Musiol, T. R. Eccleshall, P. J. Malloy and D. Feldman. Vitamin D receptor gene polymorphisms: Analysis of ligand binding and hormone responsiveness in cultured skin fibroblasts. *Biochem. Biophys. Res. Commun.* 242:467-473, 1998.
165. Gross, T. Stamey, S. Hancock, and D. Feldman. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D<sub>3</sub> (calcitriol). *J. Urology* 159:2035-2040, 1998.
166. Gross, A.V. Krishnan, P.J. Malloy, T. R. Eccleshall, X.-Y. Zhao and D. Feldman. The vitamin D receptor gene start codon polymorphism: A functional analysis of Fok I variants. *J. Bone Mineral Res.* 13: 1691-1699, 1998.
167. P.J. Malloy and D. Feldman. Molecular defects in the vitamin D receptor associated with hereditary 1,25-dihydroxyvitamin D resistant rickets. In: *Vitamin D: Physiology, Molecular Biology, and Clinical Applications*. M.F. Holick, editor. Humana Press, Totowa, New Jersey, 1999, pp 317-336.
168. X.-Y. Zhao, L.L. Ly, D.M. Peehl and D. Feldman. Induction of androgen receptor by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and 9-cis retinoic acid in LNCaP human prostate cancer cells. *Endocrinology* 140:1205-1212, 1999.
169. P. J. Malloy, J. W. Pike and D. Feldman. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D resistant rickets. *Endocrine Rev.* 20:156-188, 1999.

170. P. J. Malloy and D. Feldman. Hereditary resistance to vitamin D. In: Hormone Resistant Syndromes. L. Jameson, editor. Humana Press, Totowa, New Jersey, 1999, pp 59-85.
171. **L. Ly, X.-Y. Zhao, L. Holloway and D. Feldman.** Liarozole acts synergistically with  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> to inhibit DU 145 human prostate cancer cell growth by blocking 24-hydroxylase activity. *Endocrinology* 140:2071-2076, 1999.
172. P. J. Malloy and D. Feldman. Vitamin D Resistance. *Am. J. Med.* 106:355-370, 1999.
173. N.-G. Chen, S. F. Sarabia, P. J. Malloy, X.-Y. Zhao, D. Feldman, and G. Reaven. PPAR $\gamma$  agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression. *Biochem. Biophys. Res. Commun.* 263:718-722, 1999.
174. D. Feldman. Editorial: Vitamin D, parathyroid hormone and calcium: A complex regulatory network. *Am. J. Med.* 107:637-639, 1999.
175. X.-Y. Zhao, B. Boyle, A. Krishnan, N. Navone, D. M. Peehl and D. Feldman. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. *J. Urol.* 162:2192-2199, 1999.
176. D. Feldman, X.-Y. Zhao, A. V. Krishnan. Editorial/Mini-Review: Vitamin D and prostate cancer. *Endocrinology* 141:5-9, 2000.
177. **X.-Y. Zhao, P.J. Malloy, A.V. Krishnan, S.R. Swami, N.M. Navone, D. M. Peehl and D. Feldman,** Glucocorticoids promote androgen-independent prostate cancer cell growth via a mutated androgen receptor. *Nature Medicine* 6:703-706, 2000.
178. X.-Y. Zhao, D.M. Peehl, N.M. Navone and D. Feldman, 1,25-Dihydroxyvitamin D<sub>3</sub> inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. *Endocrinology* 141: 2548-2556, 2000.
179. P.R. Fisher, T. D. Thacher, J.M. Pettifor, L.B. Jorde, A.R. Eccleshall and D. Feldman, Vitamin D receptor polymorphisms and nutritional rickets in Nigerian children. *J. Bone Mineral Res.* 15:2206-2210, 2000.
180. S. Swami, A.V. Krishnan, and D. Feldman, 1,25-Dihydroxyvitamin D<sub>3</sub> down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. *Clin. Cancer Res.* 6: 3371-3379, 2000.
181. V. Sung and D. Feldman, 1,25-Dihydroxyvitamin D<sub>3</sub> decreases prostate cancer cell alpha 6 and beta-4 integrin expression resulting in reduced cellular adhesion and migration. *Molec. Cellular Endocrinol.* 164:133-143, 2000.
182. H. Posner, K. Crawford, M.-L. Siu-Caldera, G. S. Reddy, S. F. Sarabia, D. Feldman, E. van Etten, C. Mathieu, L. Gennaro, P. Vouros, S. Peleg, P.M. Dolan, and T. W. Kensler, Conceptually new 20-epi-oxa sulfone analogues of the hormone  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub>: Synthesis and biological

- evaluation. *J. Medicinal Chem.* 43: 3581-3586, 2000.
183. X.-Y. Zhao and D. Feldman, Antiproliferative mechanisms of 1,25-dihydroxyvitamin D<sub>3</sub> in human prostate cancer cells. *In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects*, (Eds. A.W. Norman, R. Bouillon, and M. Thomasset). Proceedings of the Eleventh Workshop on Vitamin D, Nashville, TN, May 27- June 1, 2000, pp 489-493.
184. Gardezi, C. Nguyen, P. Malloy, D. Feldman and S. Peleg, Development of a rational strategy for the treatment of hereditary vitamin D resistant rickets with analogs of 1,25 dihydroxyvitamin D<sub>3</sub>. *In: Vitamin D Endocrine System. Structural, Biological, Genetic and Clinical Aspects*, (Eds. A.W. Norman, R. Bouillon, and M. Thomasset). Proceedings of the Eleventh Workshop on Vitamin D, Nashville, TN, May 27- June 1, 2000, pp 931-934.
185. B. J. Boyle, X.-Y. Zhao, P. Cohen, and D. Feldman. Insulin-like growth factor binding protein 3 (IGFBP-3) mediates 1,25-dihydroxyvitamin D<sub>3</sub> growth inhibition in the LNCaP prostate cancer cell line. *J. Urol.* 166:1319-1324, 2001.
186. S. Swami, S.F. Sarabia, A. Diamendis, J. Mistry, J. Khosravi, and D. Feldman, A new enzyme-linked immunosorbant assay for the measurement of human vitamin D receptor. *Bone* 28:319-326, 2001.
187. V. Krishnan, S. Swami, and D. Feldman, Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. *J. Steroid. Biochem. Mol. Biol.* 77:29-37, 2001.
188. R. Linde, A. Saxena, and D. Feldman, Hypophosphatemic rickets presenting as recurring pedal stress fractures in a middle-aged woman. *J. Foot Ankle Surg.* 40:101-104, 2001.
189. X.-Y. Zhao and D. Feldman, The role of vitamin D in prostate cancer. *Steroids* 66: 293-300, 2001.
190. D. Peehl, J. Seto and D. Feldman, Rationale for combination ketoconazole/vitamin D treatment of prostate cancer. *Urology* 58:(Suppl 2A) 123-126, 2001
191. J.-Y. Hsu, D. Feldman, J. E. McNeal and D. M. Peehl, Reduced 1 $\alpha$ -hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitaminD<sub>3</sub>-induced growth inhibition. *Cancer Res.* 61:2852-2856, 2001.
192. P. J. Malloy, W. Zhu, X.-Y. Zhao, G. B. Pehling and D. Feldman, A Novel inborn error in the ligand binding domain of the vitamin D receptor causes hereditary vitamin D resistant rickets. *Mol. Genetic. Metab.* 73:138-148, 2001.
193. **J. W. Chu, D. F. Matthias, J. Belanoff, A. Schatzberg, A. R. Hoffman, and D. Feldman, Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).** *J. Clin. Endocrinol. Metab.* 86:3568-3573, 2001.
194. S. A. Gardezi, C. Nguyen, P. J. Malloy, G. H. Posner, D. Feldman and S. Peleg, A rationale for

- treatment of hereditary vitamin D resistant rickets with analogs of  $1\alpha$ , 25-dihydroxyvitamin D<sub>3</sub>. *J. Biol Chem.* 276: 29148-29156, 2001.
195. R. Marcus, D. Feldman, and J. Kelsey, *Osteoporosis*, 2nd Edition, Academic Press, San Diego, 2001, volume 1 pp 1-829; volume 2 pp 1-843.
196. D. Feldman, P. J. Malloy and C. Gross, Vitamin D: biology, action and clinical implications. In: "*Osteoporosis*", 2nd Edition, (eds. R. Marcus, D. Feldman, and J. Kelsey) Academic Press, San Diego, 2001, pp 257-304.
197. **B. J. Feldman and D. Feldman, The development of androgen independent prostate cancer.** *Nature Reviews Cancer* 1:34-45, 2001.
198. V. Krishnan, X.-Y. Zhao, S. Swami, L. Brive, D. M. Peehl, K. R. Ely, and D. Feldman, A glucocorticoid-responsive mutant androgen receptor (AR<sup>CCR</sup>) exhibits unique ligand specificity: Therapeutic implications for androgen-independent prostate cancer. *Endocrinology*, 143, 1889-1900, 2002.
199. **D. Peehl, J. Seto, J.-Y. Hsu and D. Feldman, Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analog EB1089 on prostate cancer cells.** *J. Urology* 168:1583-1588, 2002.
200. P. J. Malloy, R. Xu, L. Peng, P. A. Clark and D. Feldman, A novel mutation in helix 12 of the VDR impairs coactivator interaction and causes hereditary vitamin D resistant rickets without alopecia. *Mol. Endocrinol.* 16:2548-2546, 2002.
201. P.J. Malloy, W. Zhu, R. Bouillon and D. Feldman, A novel nonsense mutation in the ligand binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. *Mol. Genetic Metab.* 77:314-318, 2002.
202. Y. Xu, A. Shibata, J. McNeal, T.A. Stamey, D. Feldman, and D.M. Peehl, Vitamin D receptor start codon polymorphism (Fok I) and prostate cancer progression. *Cancer Epidemiol. Biomark. Prevent.* 12:23-27, 2003.
203. A. Krishnan, D. Peehl and D. Feldman, Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. *J. Cell. Biochem.* 88:363-371, 2003.
204. D.M. Peehl and D. Feldman, The role of vitamin D and retinoids in controlling prostate cancer progression. *Endocrine-Related Cancer* 10:131-140, 2003.
205. D. M. Peehl, A.V. Krishnan and D. Feldman, Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. *J. Nutrition* 133:2461S-2469S, 2003.
206. V. Krishnan, D. M. Peehl and D. Feldman. The role of vitamin D in prostate cancer. *Recent Results Cancer Res.* 164: 205-221, 2003.
207. S. Swami, X.-Y. Zhao, S. F. Saravia, M.-L. Su, M. Uskokovic, S. Reddy, and D. Feldman. A low-

calcemic vitamin D analog (Ro 25-4020) inhibits the growth of LNCaP human prostate cancer cells with increased potency by producing an active 24-oxo metabolite. *Recent Results Cancer Res.* 164:349-352, 2003.

208. D. Feldman and P.J. Malloy. Vitamin D deficiency, rickets and osteomalacia, *In: "Encyclopedia of Hormones"*, Editors A. Norman and H. Henry, Academic Press, 2003, pp 600-669.
209. S. Swami, N. Raghavachari, E. Muller and D. Feldman. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. *Breast Cancer Res. Treat.* 80:49-62, 2003.
210. P.J. Malloy and D. Feldman. Hereditary 1,25-dihydroxyvitamin D-resistant rickets. *Endocrinol. Dev.* 6:175-99 2003.
211. A.V. Krishnan, R. Shinghal, N. Raghavachari, J.D. Brooks, D.M.Peehl and D.Feldman. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. *Prostate* 59:243-251, 2004.
212. P.J. Malloy, R. Xu, A. Cattani, I. Reyes, D. Feldman, A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. *J. Bone Mineral Res.* 19:1018-1024, 2004.
213. L. Peng, P.J. Malloy and D. Feldman, Identification of a Functional Vitamin D Response Element within the Human Insulin-Like Growth Factor Binding Protein-3 Promoter. *Molec. Endocrinol.* 18:1109-1119, 2004.
214. J. F. Ma, L Nonn, M. Campbell, M. Hewison D. Feldman, D. M. Peehl, Mechanisms of decreased vitamin D 1 $\alpha$ -Hydroxylase activity in prostate cancer cells. *Molec. Cell. Endocrinol.* 221:67-74, 2004.
215. D. Feldman and P.J. Malloy, Vitamin D deficiency, rickets and osteomalacia, *In: Encyclopedia of Endocrine Diseases*, editor L. Martini, Vol. 4, Elsevier, San Diego, pp 666-673, 2004.
216. P.J. Malloy, J. W. Pike and D. Feldman, Hereditary vitamin D resistant rickets, *In: "Vitamin D"*, second edition, edited by D. Feldman, F. Glorieux and J.W. Pike, Academic Press, San Diego, pp. 1207-1238, 2005.
217. V. Krishnan, D. M. Peehl, and D. Feldman Vitamin D and prostate cancer, *In: "Vitamin D"*, second edition, edited by D. Feldman, F. Glorieux and J.W. Pike, pp. Academic Press, San Diego, pp. 1679-1708, 2005.
218. Oakley-Girvan, D. Feldman, T. R. Eccleshall, R. P. Gallagher, A. H. Wu, L. N. Kolonel, J. Halpern, R. R. Balise, D.W. West, R. S. Paffenbarger, Jr., A.S. Whittemore, Risk of Early-onset prostate cancer in relation to germline polymorphisms of the vitamin D receptor. *Cancer Epidemiol..Biomark. Prevent.* 13:1325-1330, 2004.

219. P. J. Malloy, R. Xu, L. Peng, S. Peleg, A. Al-Ashwal, and D. Feldman, Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. *Endocrinology* 145:5106-5114, 2004.
220. D.M. Peehl, R. Shinghal, L. Nonn, E. Seto, A.V. Krishnan, J.D. Brooks, D. Feldman, Molecular activity of 1,25-dihydroxyvitamin D<sub>3</sub> in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. *J Steroid Biochem Mol Biol*. 92:131-41, 2004.
221. D. M. Peehl and D. Feldman, Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer. *J Steroid Biochem Mol Biol*. 92:307-15. 2004.
222. A. Whittemore, P. Cirillo, D. Feldman and B. Cohen, Prostate-specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of African-Americans and whites. *J. Urol*, 174:872-876, 2005.
223. Y. Liu, Q. Shen, P. J. Malloy, E. Soliman, X. Peng, S. Kim, J.W. Pike, D. Feldman and S. Christakos, Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs. *J. Bone Mineral Metab*. 20:1680-91, 2005.
224. S. Swami, A. Krishnan and D. Feldman, Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D<sub>3</sub> in DU145 human prostate cancer cells: Role of the direct inhibition of CYP24 enzyme activity. *Mol. Cell Endocrinol*. 241:49-61, 2005.
225. J. Moreno, A.V. Krishnan, S. Swami, L. Nonn, D.M. Peehl, and D. Feldman, Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. *Cancer Res*. 65:7917-25, 2005.
226. J. Moreno, A. V. Krishnan and D. Feldman, Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. *J. Steroid Biochem. Mol. Biol*. 97:31-36, 2005.
227. S. Srinivas, N. Colocci, A. Krishnan, and D. Feldman, A phase II study evaluating oral triamcinolone in patients with androgen independent prostate cancer. *Urology*, 67:1001-1006, 2006.
228. L. Nonn, L. Peng, D. Feldman, D.M. Peehl, Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via MAP Kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D. *Cancer Res*. 66:4516-4524, 2006.
229. R. S. Bhattacharyya, A.V. Krishnan, S. Swami, and D. Feldman, Fulvestrant (ICI182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. *Mol. Cancer Ther*. 5: 1539-1549, 2006.
230. B. Husback, R. S. Bhattacharyya, D. Feldman, and S. Knox, Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: Two distinct mechanisms of action. *Mol. Cancer Ther*. 5:2078-85, 2006.

231. C.J. Tsai, B. A. Cohn, P. M. Cirillo, D. Feldman, F.Z. Stanczyk, and A.S. Whittemore, Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians. *Cancer Causes Control* 17:1237-1244, 2006.
232. J. Moreno, A.V. Krishnan, D.M. Peehl, D. Feldman, Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. *Anticancer Res* 26: (4A) 2525-30, 2006.
233. L. Peng, P.J. Malloy, J. Wang and D. Feldman, Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 (IGFBP-3) expression via an androgen response element in LNCaP human prostate cancer cells. *Endocrinology* 147:4599-607, 2006.
234. P.J. Malloy, J. Wang, L. Peng, S. Nayak, J.M. Sisk, C.C. Thompson and D. Feldman, A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. *Arch Biochem Biophys.* 460:285-292, 2006.
235. A.V. Krishnan, J. Moreno, L. Nonn, P. Malloy, S. Swami, L. Peng, D. M. Peehl and D. Feldman, Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. *J Steroid Biochem. Mol. Biol.* 103:694-702, 2007. PMID 17229571
236. S. Swami, A.V. Krishnan, J. Moreno, R. B. Bhattacharyya, D.M. Peehl, and D. Feldman, Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. *J Nutr.* 137:205S-210S, 2007. PMID 17182827
237. J. Wang, P.J. Malloy and D. Feldman, Interactions of the vitamin D receptor with the corepressor hairless: Analysis of hairless mutants in atrichia with papular lesions. *J Biol Chem.* 282: 25231-25239, 2007. PMID 17609203
238. A. V. Krishnan, S. Swami, J. Moreno, R. B. Bhattacharyya, D. M. Peehl, and D. Feldman Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein. *Nutr Rev.* 65(8 Pt 2):S121-3, 2007. PMID 17867387
239. D. Feldman, A.V. Krishnan, J. Moreno, S. Swami, D.M. Peehl, S. Srinivas, Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. *Nutr. Rev.* 65(8 Pt 2):S113-5, 2007. PMID 17867384
240. L. Peng, J. Wang, P.J. Malloy, D. Feldman, The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. *Int. J. Cancer.* 2008 122:558-66, 2008. PMID 19056816
241. A.V. Krishnan, J. Moreno, L. Nonn, S. Swami, D.M. Peehl, and D. Feldman, Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. *J Bone Miner Res.* 22 Suppl 2:V74-80. 2007.

242. D. Feldman, P.J. Malloy, A.V. Krishnan, and E. Balint, Vitamin D: Biology, action and clinical implications, *In: "Osteoporosis, Third Edition"*, edited by R. Marcus, D. Feldman, D.A. Nelson and C.J. Rosen, Elsevier/Academic Press, pp 317-382, 2008.
243. R.S. Bhattacharyya, B. Husbeck, D. Feldman, and S.J. Knox, Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 72:935-940, 2008. PMID 18760546
244. P.J. Malloy and D. Feldman, Inactivation of the human vitamin D receptor by Caspase-3. *Endocrinology*. 150:679-686, 2009. PMID 18832097
245. S. Swami, A.V. Krishnan, J. Moreno, R.S. Bhattacharyya, C. Gardner, J.D. Brooks, D.M. Peehl and D. Feldman, Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. *Int. J. Cancer* 124:2050-2059, 2009. PMID 19127598
246. S. Srinivas and D. Feldman, A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. *Anti-Cancer Res.* 29:3605-3610, 2009. PMID 19667155
247. P. J. Malloy, L. Peng, J. Wang, and D. Feldman, Interaction of the vitamin D receptor with a vitamin D response element in the Müllerian Inhibiting Substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. *Endocrinology* 150:1580-1587, 2009. PMID 19056816
248. Y. Zhou, J. Wang, P. J. Malloy, Z. Dolezel and D. Feldman, Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia. *J. Bone Mineral Res.* 24:643-651, 2009. PMID 19049339
249. A.V. Krishnan, S. Srinivas and D. Feldman, Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. *Dermato-Endocrinology* 1:7-11, 2009. PMID 20046582
250. C.D. Gardner, B. Oelrich, J. Liu, D. Feldman, A. Franke and J.D. Brooks, Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. *Prostate* 69:719-26, 2009. PMID 19180569
251. A. Krishnan and D. Feldman, Anti-inflammatory activity of calcitriol that contributes to its therapeutic and chemopreventive effects in prostate cancer. *In: "Vitamin D: Physiology, Molecular Biology and Clinical Applications"* edited by M.F. Holick, Humana Press, Totowa NJ, 2009 pp1087-1104.
252. P.J. Malloy and D. Feldman, Molecular Defects in the Vitamin D Receptor Associated with Hereditary 1,25-Dihydroxyvitamin D Resistant Rickets (HVDRR). *In: "Vitamin D: Physiology, Molecular Biology and Clinical Applications"* edited by M.F. Holick, Humana Press, Totowa NJ, 2009 pp 691-714.
253. S. Jogie-Brahim, D. Feldman, Y. Oh. Unraveling IGFBP-3 Actions in Human Disease. *Endocr Rev.* 30(5):417-37, 2009. PMID 19477944

254. N.S. Ma, P.J. Malloy, P. Pitukcheewanont, D. Dreimane, M.E. Geffner, and D. Feldman. Hereditary vitamin D resistant rickets: Identification of a novel splice site mutation in the vitamin D receptor gene and successful treatment with oral calcium therapy. *Bone* 45:743-746, 2009. PMID 19523546
255. P.J. Malloy, J. Wang, K. Jensen and D. Feldman, Modulation of vitamin D receptor activity by the corepressor hairless: differential effects of hairless isoforms. *Endocrinology* 150:4950-4957, 2009. PMID 19819974
256. D.N. LeVine, Y. Zhou, R.J. Ghiloni, E.L. Fields, A.J. Birkenheuer, J.L. Gookin, I.D. Roberston, P.J. Malloy, and D. Feldman, Hereditary 1,25-dihydroxyvitamin D-resistant rickets in a Pomeranian dog caused by a novel mutation in the vitamin D receptor gene *J. Veterin. Internal Med.* 23:1278-1283, 2009. PMID 19909429
257. P.J. Malloy, J. Wang, T. Srivastava and D. Feldman; Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. *Molec. Genetic Med.* 99:72-79, 2010. PMID 19815438
258. A.V. Krishnan, S. Swami, L. Peng, J. Wang, J. Moreno and D. Feldman, Tissue-selective regulation of aromatase expression by calcitriol: Implications for breast cancer therapy. *Endocrinology*, 151:4950-4957, 2010. PMID 19906814
259. A. V. Krishnan and D. Feldman, Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. *Endocrine Related Cancer*, 17:R19-38, 2010. PMID 19926709
260. A.V. Krishnan, S. Swami, D. Feldman, Vitamin D and breast cancer: Inhibition of estrogen synthesis and signaling. *J. Steroid Biochem. Mol. Biol.* 121:343-348, 2010. PMID 20156557
261. N. Forghani, C. Lum, S. Krishnan, J. Wang, D. Wilson, P.R. Blackett, P.J. Malloy, and D. Feldman, Two new unrelated cases of hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from the same novel nonsense mutation in the vitamin D receptor gene. *J. Pediatr. Endocrinol. Metab.* 23:843-850, 2010. PMID: 21073129
262. P.J. Malloy, and D. Feldman, Genetic disorders and defects in vitamin D action. *Endocrinol Metab Clin N Am* 39: 333-346, 2010. PMID 20511055
263. A.V. Krishnan, D.L. Trump, C.S. Johnson, D. Feldman, The Role of Vitamin D in Cancer Prevention and Treatment. *Endocrinol Metab Clin N Am* 39:401-418, 2010. PMID 20511060
264. R.S. Mason, V.B. Sequeira, K.M. Dixon, C. Gordon-Thomson, K. Pobre, A. Dilley, M.T. Mizwicki, A.W. Norman, D. Feldman, G.M. Halliday, V.E. Reeve, Photoprotection by 1alpha, 25-dihydroxyvitamin D and analogs: Further studies on mechanisms and implications for UV-damage. *J Steroid Biochem Mol Biol*, 121:164-168, 2010. PMID 20399269
265. R. Linde, L. Peng, M. Desai, and D. Feldman, The role of vitamin D and SLCO1B1 gene

polymorphism in statin-associated myalgias. Dermatoendocrinol 2:77-84, 2010. PMID 21547103

266. A.V. Krishnan and D. Feldman, Anti-inflammatory activity of calcitriol in cancer. In "Vitamin D and Cancer" edited by D.L. Trump and C.S. Johnson, Springer, New York, 2011 pp 53-72.
267. A.V. Krishnan and D. Feldman, Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 51:311-336, 2011. PMID 20936945
268. P.J. Malloy, D. Tiosano, and D. Feldman, Hereditary 1,25-dihydroxyvitamin D resistant rickets. In: "Vitamin D" 3<sup>rd</sup> Edition edited by D. Feldman, J.W. Pike, and J. Adams, Elsevier/Academic Press, 2011, pp 1197-1232.
269. A.V. Krishnan and D. Feldman, Vitamin D and prostate cancer. In: "Vitamin D" 3<sup>rd</sup> Edition edited by D. Feldman, J.W. Pike, and J. Adams, Elsevier/Academic Press, 2011, pp 1675- 1710.
270. J.P.T.M. van Leeuwen, M. van Driel, D. Feldman, A. Munoz, Vitamin D: cancer and differentiation. In: "Vitamin D" 3<sup>rd</sup> Edition edited by D. Feldman, J.W. Pike, and J. Adams, Elsevier/Academic Press, 2011, pp1591-1624.
271. J.Y. Tang, T. Fu, E.S. LeBlanc, J.E. Manson, D. Feldman, E. Linos, M.Z. Vitolins, N. Zeitouni, J. Larson, and M.L. Stefanick, Calcium plus vitamin D supplementation and the risk of non-melanoma and melanoma skin cancer. J. Clin. Oncol. 29:3078-84, 2011. PMID:21709199
272. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, L. Peng, M.A. Albertelli and D. Feldman. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo. Horm. Cancer 23:190- 202, 2011. PMID 21686077
273. M.A. Regueira, S. Shaonly, P.J. Malloy, P. Ordonez-Morán, D.I. Resende, F.S. Sussman, A. Munoz, A. Mouríño, D. Feldman, and M. Torneiro, Synthesis and biological evaluation of 1 $\alpha$ , 25-dihydroxyvitamin D<sub>3</sub> analogs hydroxymethylated at C-26. J Med. Chem. 54:3950-3962, 2011. PMID 2152407
274. S. Swami, A. Krishnan and D. Feldman, Vitamin D metabolism and action in the prostate: Implications for health and disease. Mol. Cell. Endocrinol. 347:61-69, 2011. PMID:21664249
275. P.J. Malloy, D. Feldman, The role of vitamin D receptor mutations in the development of alopecia. Mol. Cell. Endocrinol. 347:90-96, 2011. PMID: 21693169
276. J.M. Aljubeh, J. Wang, S.S. Al-Remeithi, P.J. Malloy, and D. Feldman, Report of two unrelated patients with hereditary vitamin D resistant rickets due to the same novel mutation in the vitamin D receptor. J. Pediatr. Endocrinol. Metab. 24:793-799, 2011. PMID 22145479
277. E. Vanoorbeek, A. Krishnan, G. Eelen, L. Verlinden, R. Bouillon, D. Feldman and A. Verstuyf, The anti-cancer and anti-inflammatory actions of 1,25(OH)<sub>2</sub>D<sub>3</sub>. Best Pract. Res. Clin. Endocrinol. Metab. 25:593-604, 2011. PMID 21872801

278. P.J. Malloy, Y. Zhou, J. Wang, O. Hiort and D. Feldman, Hereditary vitamin D resistant rickets (HVDRR) owing to a heterozygous mutation in the vitamin D receptor. *J. Bone Miner. Res.* 26:2710-2018, 2011. PMID 21812032.
279. V.B. Sequeira, M.S. Rybchyn, W.Tongkao-on, C. Gordon-Thomson, P.J. Malloy, I. Nemere, A.W. Norman, V.E. Reeve, G.M. Halliday, D. Feldman, Rebecca S. Mason, The role of the vitamin D receptor and ER $\alpha$ 57 in photoprotection by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. *Mol. Endocrinol.* 26:574-582, 2012. PMID 22322599
280. C. Lamendola, D. Ariel, D. Feldman, G. Reaven, Relationships among obesity, insulin resistance, and 25-hydroxyvitamin D. *Amer. J. Clin. Nutr.* 95:1055-59, 2012. PMID 22440850
281. J. Y. Wang, S. Swami, A. V. Krishnan, and D. Feldman, Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer, *The Prostate*, 72:1628-1637, 2012. PMID 22457201
282. S. Swami, A.V. Krishnan, J.Y. Wang, K. Jensen, R. Horst, M.A. Albertelli and D. Feldman, Dietary vitamin D<sub>3</sub> and 1,25-dihydroxyvitamin D<sub>3</sub> (Calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. *Endocrinology*, 153:2576-2587, 2012. PMID 22454149
283. P.J. Malloy, and D. Feldman, Genetic disorders and defects in vitamin D action. *Rheum Dis Metab Clin N Am* 38: 93-106, 2012. PMID: 22525845
284. A.V. Krishnan, D.L. Trump, C.S. Johnson, D. Feldman, The role of vitamin D in cancer prevention and treatment. *Rheum Dis Metab Clin N Am* 38:161-178, 2012. PMID: 22525850
285. A.V. Krishnan, S. Swami, D. Feldman, The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. *Steroids*. 77:1107-1112, 2012. PMID: 22801352.
286. D. Feldman, P. J. Malloy and W.L. Miller, Genetic Disorders of Vitamin D Synthesis and Action *In “Genetics of Bone Biology and Skeletal Disease”*, Edited by R. Thakker, M.P. Whyte, J. Eisman, and T. Igrashi, 2012, Elsevier, San Diego, pp 537-552.
287. M. Basina, H. Liu, A.R. Hoffman, D. Feldman D. Successful Long-term treatment of Cushings Disease with Mifepristone (RU486). *Endocr Pract Sept-Oct* e114-120, 2012. PMID: 22441000
288. D. Feldman, A.V. Krishnan, and S. Swami, Vitamin D: Biology, Actions and Clinical Implications *In “Osteoporosis”*, 4<sup>th</sup> Edition, edited by R. Marcus, D. Feldman, D. Dempster, M. Luckey, and J.A. Cauley. Academic Press/Elsevier, San Diego 2013 pp 283-328.
289. A.V. Krishnan, S. Swami and D. Feldman, Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention. *J Steroid Biochem Mol Biol* 136:289-295, 2013, PMID:22939886

290. K. Huang, P. Malloy, D. Feldman, P. Pitukcheewanont. Enteral calcium infusion used successfully as treatment for a patient with hereditary vitamin D resistant rickets (HVDRR) without alopecia: A novel mutation. *Gene* 512:554-9. Epub 2012 Sep 28. PMID:23026218
291. S. Swami, A. V. Krishnan, L. Peng, J. Lundqvist, and D. Feldman. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. *Endocr Relat Cancer.* 2013 Jun 6. [Epub ahead of print] PMID: 23744764
292. L. Katznelson, D. L. Loriaux, D. Feldman, G. D. Braunstein, D. E. Schteingart, C. Gross. Global clinical response in Cushing's Syndrome patients treated with mifepristone, *Clin Endocrinol (Oxf).* 2013 Sep 19. doi: 10.1111/cen.12332. [Epub ahead of print]
293. P.J.Malloy, V. Tasic, D. Taha D, F. Tütüncüler, G.S. Ying, L.K. Yin, J. Wang, and D. Feldman. Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D resistant rickets. *Mol Genet Metab* 2014 Jan;111(1):33-40. doi: 10.1016/j.ymgme.2013.10.014. Epub 2013 Nov 4. PMID: 24246681
294. D. Feldman and P. J. Malloy, Mutations in the Vitamin D Receptor and Hereditary Vitamin D-Resistant Rickets. *BoneKey Reports* 3:510, edited by R. Bouillon Article Number 510, 2014, Internatl. Bone & Mineral Society doi:10.1038/Bonekey Rep. PMID 24818002
295. **D. Feldman, A. V. Krishnan, S. Swami, E. Giovannucci and B. J. Feldman. The role of vitamin D in reducing cancer risk and progression. *Nature Rev Cancer* 14:343-357, 2014 PMID 24705652**
296. F. Abbasi, D. Feldman, M. P. Caulfield. F. M. Hantash, G. M. Reaven, Relationship among 25-Hydroxyvitamin D Concentrations, Insulin Action, and Cardiovascular Disease Risk in Patients with Essential Hypertension. *Amer J Hypertens* 28:266-272, 2015 PMID 25138785
297. F. Abbasi, C. Blasey, D. Feldman, M.P. Caulfield, F.M. Hantash, and G.M. Reaven. Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes. *J Nutrition* 145:1-6, 2015
298. Y. Jeong, S. Swami, A. V. Krishnan, J. D. Williams, S. Martin, R. L. Horst, M. A. Albertelli, B. J. Feldman, D. Feldman and M. Diehn. Inhibition of mouse breast tumor initiating cells by calcitriol and vitamin D. *Mol Cancer Ther* 14: 342-57, 2015 PMID 25934710.
299. **S. Narayanan, S Srinivas and D. Feldman. Androgen – Glucocorticoid Interactions in the Era of Novel Antiandrogen Therapy for Prostate Cancer. *Nature Reviews Urology* 13: 47-60, 2016, PMID 26643568.**
300. S. Swami, A.V. Krishnan, J. Williams, A. Aggarwal, M.A. Albertelli, R.L. Horst, B. J. Feldman and D. Feldman. Vitamin D mitigates the adverse effects of obesity on the growth of breast cancer in mice. *Endocr Relat Cancer* 23:261-264, 2016, PMID 26817629.

301. G. Kwon, C. Gamba, M. Stefanick, S.M. Swetter, S. Li, R. Shi, C.A. Clarke, D. Feldman, A. Millen, C. Messina, J. Shikany, J. Manson, R. Chlebowski and J. Tang. Association of 25-hydroxyvitamin D levels and cutaneous melanoma in postmenopausal women in the Women's Health Initiative study. *J Invest Derm* 136 S24, 2016
302. J. Lundqvist, T. Kirkegaard, A.V. Laenkholm, A.K. Duun-Henriksen, M. Bak, D. Feldman, A.E. Lykkesfeldt. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1 $\alpha$ ,25-dihydroxyvitamin D3. *Steroid Biochem Mol Biol.* 2017 Jun 10. [Epub ahead of print] PMID: 28610873.
303. A. Aggarwal, D. Feldman, B.J. Feldman. Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression. *J Steroid Biochem Mol Biol.* 2017 Jul 11. pii: S0960-0760(17)30167-X. doi: 10.1016/j.jsbmb.2017.07.003. [Epub ahead of print] Review. PMID: 28710021.
304. D. Feldman, B. C. J. van der Erden, P.J. Malloy and W. L. Miller. Genetic disorders of vitamin D synthesis and action. In *Genetics of Bone Biology and Skeletal Disease*, 2nd Edition,. Edited by R.V. Thakker, M.P. White, J.A. Eisman and T. Igarashi, Elsevier/Academic Press, San Diego, 2017.
306. C.C. Going, L. Alexandrova, K. Lau, C.Y. Yeh, D. Feldman, S.J. Pitteri. Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial. *Breast Cancer Res Treat.* 2017 Nov 7. doi: 10.1007/s10549-017-4562-4. [Epub ahead of print] PMID: 29116467
307. G. D. Abrams, D. Feldman, M.R. Safran. Vitamin D effects on skeletal muscle and athletic performance. *J. Amer Assoc Orthoped Surg*, 2018 Apr 15;26(8):278-285, 2018. PMID:29561306
308. Neighbors CLP, Noller MW, Song SA, Zaghi S, Neighbors J, Feldman D, Kushida CA, Camacho M. Vitamin D and obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Med.* 2018 43:100-108. PMID: 29482804

## Edited Books

- R. Marcus, D. Feldman and J. Kelsey, editors. Osteoporosis, Academic Press, Inc., San Diego, 1996, pp 1-1373.
- D. Feldman, F. Glorieux, and J.W. Pike, editors. Vitamin D, Academic Press, Inc., San Diego, 1997. pp 1-1285.
- R. Marcus, D. Feldman, and J. Kelsey, Osteoporosis, 2nd Edition, Academic Press, San Diego, 2001, volume 1 pp 1-829; volume 2 pp 1-843.
- D. Feldman, J.W. Pike and F. Glorieux, editors, Vitamin D 2nd Edition, Academic Press, Inc., San Diego, 2005.
- R. Marcus, D. Feldman, C. Rosen, D. Nelson, editors, Osteoporosis 3rd Edition, Academic Press/Elsevier,

San Diego, 2007.

- R. Marcus, D. Feldman, C. Rosen, D. Nelson, editors, Fundamentals of Osteoporosis, Academic Press/ Elsevier, San Diego, 2009.
- D. Feldman, J.W. Pike and J. Adams, editors, Vitamin D 3rd Edition, Academic Press/ Elsevier, Inc., San Diego, 2011.
- R. Marcus, D. Feldman, D. Dempster, M. Luckey, and J.A. Cauley, editors, Osteoporosis 4th Edition, Academic Press/Elsevier, San Diego, 2013
- D. Feldman, J.W. Pike, R. Bouillon, E. Giovannucci D. Goltzman and M. Hewison, editors, Vitamin D 4th Edition, Academic Press/ Elsevier, Inc., San Diego, 2018.